Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such ...
Alterity Therapeutics Limited (ATHE) is a clinical-stage biotechnology company whose mission is to create an “alternate future” for people living with neurodegenerative diseases, positioning its work around the goal of developing disease-modifying or otherwise meaningful therapies for conditions such as Parkinson’s, Alzheimer’s, and related disorders. The company’s business model is ...Alterity Therapeutics Limited (ATHE) is a clinical-stage biotechnology company whose mission is to create an “alternate future” for people living with neurodegenerative diseases, positioning its work around the goal of developing disease-modifying or otherwise meaningful therapies for conditions such as Parkinson’s, Alzheimer’s, and related disorders. The company’s business model is typical for small, R&D-intensive biopharma: it invests heavily in research and clinical development rather than generating sustained operating profits today.
From a product and services perspective, Alterity’s core activities center on the discovery and development of novel therapeutic approaches. The company’s pipeline highlights include ATH434, an experimental therapy that has completed Phase I clinical trials for Parkinson’s disease, and PBT2, a compound that has progressed through Phase IIa testing for Alzheimer’s disease. These programs imply ongoing work across preclinical-to-clinical translation, clinical trial execution, regulatory interactions, and supporting activities such as trial design, patient recruitment, safety monitoring, and data analysis.
Cost structure and financial signals in the provided ttm metrics reinforce the company’s development-stage profile. Financial ratios indicate negative profitability (e.g., negative operating and net profit margins) and negative free cash flow measures, consistent with a business prioritizing R&D expenditures over near-term revenue generation. While liquidity-related metrics (such as a high current ratio) suggest the company maintains the ability to fund operations through available current resources, cash generation from operations still appears weak given the negative operating cash flow and margins.
In terms of corporate footprint and human capital, the company is small. The provided sources show roughly 9 full-time employees (with historical counts around the low teens), which is consistent with a lean clinical organization that likely relies on external partners, contract research organizations (CROs), and specialized clinical/medical services to execute trials.
Key leadership is centered on David A. Stamler, who serves as Chief Executive Officer (appointed January 2021). The company has been publicly referenced as having roots dating to 1997, including prior operating history under a different name (Prana Biotechnology Limited) before rebranding to Alterity Therapeutics Limited in April 2019.
Overall, the “wish” or strategic direction implied by the company’s messaging and pipeline focus is to advance its lead candidates through later clinical stages toward potential commercialization or further licensing/partnering opportunities—while navigating the financial realities of early-to-late clinical development for neurodegenerative diseases. The combination of targeted indications (Parkinson’s and Alzheimer’s) and progression to Phase I/IIa suggests a pathway intended to generate clinical evidence that can support regulatory and investment milestones.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
-100.0%
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-22.9M
-88.4%
-48.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$0
+100.0%
+100.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.5%
+23.5%
-50.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
14.52x
+11.9%
+69.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
